Welcome to our dedicated page for Summit Therapeutics news (Ticker: SMMT), a resource for investors and traders seeking the latest updates and insights on Summit Therapeutics stock.
Summit Therapeutics Inc. (NASDAQ: SMMT) is a biopharmaceutical oncology company whose news flow is closely tied to the development of its lead investigational therapy, ivonescimab (SMT112 in Summit’s territories). Ivonescimab is described by the company as a potential first-in-class bispecific antibody targeting PD-1 and VEGF in a single molecule, and it is being evaluated in multiple Phase III clinical trials in non-small cell lung cancer (NSCLC) and colorectal cancer (CRC).
News about Summit frequently covers clinical milestones for ivonescimab, including updates from the global Phase III HARMONi trial in EGFR-mutated NSCLC after third-generation EGFR TKI therapy, as well as HARMONi-3 and HARMONi-7 in first-line metastatic NSCLC and HARMONi-GI3 in first-line unresectable metastatic CRC. Company announcements have highlighted progression-free survival and overall survival data, hazard ratios, response rates, and safety profiles, along with presentations at major conferences such as the World Conference on Lung Cancer, SITC, and ESMO.
Investors following SMMT news will also see regulatory and corporate updates, including Summit’s submission of a Biologics License Application to the U.S. FDA for ivonescimab plus chemotherapy in EGFR-mutated NSCLC, Fast Track designation for the HARMONi setting, and summaries of Akeso’s HARMONi-A trial in China, which demonstrated a statistically significant overall survival benefit for ivonescimab plus chemotherapy versus chemotherapy alone.
Additional news items cover financing activities such as private placements and at-the-market offerings, inducement stock option grants under Nasdaq Listing Rule 5635(c)(4), and collaboration announcements. Notably, Summit has reported a clinical trial collaboration with GSK plc to evaluate ivonescimab in combination with GSK’s investigational B7-H3-targeting antibody-drug conjugate, risvutatug rezetecan (GSK’227), across multiple solid tumor settings including small cell lung cancer.
For readers tracking SMMT, the news stream provides insight into Summit’s late-stage oncology pipeline, regulatory interactions, capital-raising efforts, and partnerships that shape the company’s development path.
Summary not available.
Summit Therapeutics Inc. (NASDAQ: SMMT) announced an impending expiration of its rights offering at 5:00 PM EDT on May 10, 2021. Shareholders must act quickly, as brokerage deadlines may begin today, May 5. The offering entails up to 14,312,977 shares with a total value of up to $75 million. The subscription price will be the lower of $5.24 or the volume-weighted average price over the last ten trading days. Notably, CEO Robert Duggan plans to exercise both his basic and oversubscription rights.
Summit Therapeutics announces a rights offering to raise up to $75 million by issuing 14,312,977 shares of common stock. The offering, effective April 21, 2021, allows existing stockholders, as of April 9, 2021, to purchase shares at $5.24 each or at a lower volume-weighted average price if applicable. Subscription rights must be exercised by May 10, 2021. Non-transferable rights will have no value if not exercised before the expiration date. Further details can be found in the prospectus filed with the SEC.
Summit Therapeutics (NASDAQ: SMMT) announced a rights offering for all stockholders as of April 9, 2021, allowing shares to be purchased at a maximum of $5.24 each. The offering could raise up to $75 million. Additionally, Executive Chairman Robert W. Duggan, holding 69% of shares, is expected to fully participate. The company also issued a $55 million promissory note, with an interest rate projected at 2.4%. Funds will support ongoing clinical trials for ridinilazole and other development efforts.
Summit Therapeutics Inc. (NASDAQ: SMMT) reported its financial results for Q4 and full year 2020, showing a net loss of $52.7 million compared to $29.1 million in 2019. As of March 12, 2021, the company has enrolled 581 patients in its Phase 3 Ri-CoDIFy clinical trials for ridinilazole, aiming to treat C. difficile infection with a target of 1,360 patients. Financial support from BARDA has reached $53.3 million, with a potential total of $72.5 million. The company ended 2020 with cash and equivalents of $66.4 million, sufficient to cover expenses into Q4 2021.
Summit Therapeutics announced the appointment of Dr. Mahkam Zanganeh as Chief Operating Officer, effective immediately. Previously a board member, Dr. Zanganeh brings strategic leadership and extensive operational expertise. Her past experience includes roles at Pharmacyclics, where she played a pivotal role in licensing deals. The company aims to enhance treatment for C. difficile infections through its lead candidate, ridinilazole, currently in Phase 3 trials. The leadership change is expected to strengthen the company’s position in antibiotic innovation.
Summit Therapeutics Inc. (NASDAQ: SMMT) reported its financial results for Q3 and nine months ending September 30, 2020. Patient enrollment in the Phase 3 Ri-CoDIFy trials for ridinilazole reached 448 as of November 15, 2020. However, uncertainties due to COVID-19 have led to a withdrawal of public commentary on trial completion timing. Financial highlights include cash and cash equivalents of $21.3 million, down from $63.8 million in December 2019, and a net loss of $39.3 million for the nine months ended September 30, 2020, up from $20.0 million in the same period the previous year.
Summit Therapeutics has successfully completed a $50 million private placement, issuing shares of common stock to its CEO, Robert W. Duggan, and two additional investors. A total of 14,071,856 shares were sold to Duggan and 898,204 shares to other investors at a price of $3.34 per share, matching the previous Nasdaq closing price. The proceeds are expected to support the Ri-CoDIFy Phase 3 clinical trial for ridinilazole and other early-stage projects, extending the company's cash runway into Q4 2021.
Summit Therapeutics announced a fundraising agreement worth approximately $50 million with CEO Robert W. Duggan. This private placement involves issuing up to 14,970,060 shares at a price of $3.34 per share, with a minimum of 9,730,539 shares to be sold. The funds will extend the company's cash runway into the third quarter of 2021, supporting the ongoing Ri-CoDIFy Phase 3 clinical trial for ridinilazole and preparatory activities for its potential commercial launch.
Summit Therapeutics Inc. has successfully redomiciled to Delaware, completing a scheme that transforms it from a UK company to a US-based entity. The High Court of Justice in England sanctioned the arrangement, leading to an exchange rate of five ordinary shares of Summit Therapeutics plc for one share of common stock of Summit Therapeutics Inc. Trading in the new shares on Nasdaq under the ticker SMMT will commence on September 21, 2020. Summit is focused on innovative antibiotic development, particularly for Clostridioides difficile infections.